Glaucoma vs Macular Degeneration — Clinical Trial Comparison
Glaucoma
Progressive optic nerve damage, often from high eye pressure
VS
Macular Degeneration
Central vision loss from retinal deterioration (AMD)
Glaucoma and age-related macular degeneration (AMD) are the two leading causes of irreversible sight loss in the UK. Both are age-related and manageable but not reversed. Glaucoma trials focus on better intraocular pressure control through new medications, lasers, and minimally invasive surgery, while AMD trials have been transformed by anti-VEGF therapies and are now exploring longer-acting treatments and gene therapy.
Key Differences at a Glance
| Feature | Glaucoma | Macular Degeneration |
|---|---|---|
| Primary symptoms | Peripheral vision loss (often asymptomatic early), tunnel vision | Central vision distortion, blurred central vision, straight lines appearing wavy |
| Common subtypes | POAG, angle-closure, normal-tension, congenital, secondary | Dry AMD (atrophic), wet AMD (neovascular), early, intermediate, advanced |
| Severity scoring | Visual field loss (MD, PSD), optic nerve cup-to-disc ratio, IOP | VA (visual acuity), OCT retinal thickness, drusen size/number, GA area |
| Key distinction | Peripheral vision loss, often painless | Central vision loss, distortion |
| NICE first-line | Prostaglandin analogue eye drops, laser trabeculoplasty | Anti-VEGF injections (aflibercept, ranibizumab, faricimab for wet AMD) |
| Prevalence in UK | ~700,000 (many undiagnosed) | ~700,000 (wet: ~40,000 new cases/year) |
Clinical Trial Availability
| Trial Aspect | Glaucoma | Macular Degeneration |
|---|---|---|
| UK trials actively recruiting | 20-35 studies | 25-40 studies |
| Most common trial phase | Phase 2-3 | Phase 2-3 |
| Top interventions tested | New eye drops, MIGS devices, laser procedures, sustained-release implants | Anti-VEGF (new agents, longer intervals), gene therapy, complement inhibitors, stem cells |
| Surgical trials | Active (MIGS, trabeculectomy, tube shunts) | Limited (subretinal injection for gene therapy) |
| Gene therapy trials | Emerging (neuroprotection genes) | Active (ADVM-022, RGX-314 for wet AMD) |
| Neuroprotection trials | Active (preserving retinal ganglion cells) | Active (preserving photoreceptors in dry AMD) |
Exciting Emerging Treatments
Glaucoma Trials
- Sustained-release implants — bimatoprost implant for continuous IOP control
- Minimally invasive glaucoma surgery (MIGS) — safer, faster recovery
- Rho kinase inhibitors — new mechanism for IOP reduction (netarsudil)
- Selective laser trabeculoplasty (SLT) trials — optimising first-line laser treatment
- Neuroprotective agents — protecting optic nerve independent of IOP
- Remote monitoring — home IOP measurement and visual field testing
Macular Degeneration Trials
- Longer-acting anti-VEGF — faricimab, high-dose aflibercept extending treatment intervals
- Gene therapy (ADVM-022, RGX-314) — one-time treatment potentially replacing regular injections
- Complement inhibitors — pegcetacoplan, avacincaptad for geographic atrophy (dry AMD)
- Stem cell therapy — replacing damaged retinal pigment epithelium cells
- Port delivery system — surgically implanted refillable drug reservoir
- Artificial vision — retinal implants and visual cortex stimulation
💡 Not sure which trials you qualify for?
Use our Smart Matcher to answer a few questions about your condition and we'll find the most relevant trials for your specific situation — free, instant results.
Eligibility Differences
Glaucoma Trial Criteria
- Confirmed glaucoma diagnosis with visual field loss and/or optic nerve damage
- IOP measurement required (baseline and target)
- Visual field testing (Humphrey) documenting extent of loss
- Prior treatment history documented (medications, laser, surgery)
- Some trials require specific glaucoma subtype or severity stage
Macular Degeneration Trial Criteria
- Confirmed AMD diagnosis with OCT and fluorescein angiography
- Wet AMD trials: active choroidal neovascularisation on imaging
- Dry AMD trials: geographic atrophy confirmed on OCT and fundus imaging
- Visual acuity thresholds commonly specified (e.g., VA 20/40 to 20/400)
- Prior anti-VEGF treatment history documented (treatment-naive vs experienced)
Macular Degeneration Trials
Find actively recruiting macular degeneration trials across the UK
Macular Degeneration TrialsFrequently Asked Questions
Can I join a clinical trial if I have both Glaucoma and Macular Degeneration?
It depends on the specific trial. Many trials allow comorbid conditions as long as the primary condition being studied is clearly dominant. Some trials explicitly exclude patients with significant overlapping conditions. Always check the eligibility criteria carefully and discuss with both the trial team and your specialist.
Which condition has more clinical trials available in the UK?
Both Glaucoma and Macular Degeneration have robust research pipelines with new studies opening regularly. The number of trials varies over time as new studies launch and others complete. Check our condition pages for the most current trial availability.
What should I consider when choosing between trials for these conditions?
Consider which condition impacts your quality of life most, what treatments you've already tried, the trial phase (earlier phases are more experimental), the time commitment involved, and whether the trial offers access to treatments not otherwise available. Your specialist can help you prioritise.